menu search

Harmony stock tanks on study miss for narcolepsy drug: problems may be escalating

Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings ...

October 13, 2023, 4:01 pm

Zevra therapeutics presents design of phase 2 clinical trial investigating kp1077 for the treatment of idiopathic hypersomnia (ih) at beyond sleepy 2023

Zevra is a corporate sponsor of the hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fl...

June 3, 2023, 11:30 am

Jazz pharmaceuticals to present advancements in neuroscience at american academy of neurology annual meeting

Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorde...

April 19, 2023, 7:45 am

Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder

KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmeth...

January 20, 2022, 7:00 am

Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder

KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmeth...

January 20, 2022, 7:00 am

Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder

KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmeth...

January 20, 2022, 7:00 am


Search within

Pages Search Results: